Antibe Therapeutics Inc. Announces Change In CFO Position And Granting Of Employee Stock Options

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE) today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013.

Samira Sakhia has been named the Company’s CFO on an interim basis replacing Dr. Bumby. Ms. Sakhia, currently a member of Antibe’s board of directors, brings a wealth of experience to the CFO role. She was the CFO of Paladin Labs Inc. for 13 years, responsible for leading the finance, operations, human resources, and investor-relations teams.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC